Adult patients living with type 2 diabetes now have a new treatment option available that may help them get the most out of their care. King Pharmaceuticals, Inc. (NYSE: KG) and Depomed, Inc. (NASDAQ: DEPO) today announced the commercial availability of Glumetza(TM) (metformin hydrochloride extended release tablets) in the United States. Glumetza, an oral treatment for type 2 diabetes, offers the benefits of metformin, including reliable glycemic control, absence of weight gain, and a low incidence of hypoglycemia, with the added convenience of once-daily dosing. Glumetza tablets utilize patented AcuForm(TM) technology, a novel drug-delivery system that provides controlled and prolonged release of metformin. Metformin is the only medication recommended by the American Diabetes Association (ADA) for first-line treatment of type 2 diabetes.
